Acrux

Acrux Revenue per Employee

The Revenue per Employee of Acrux (ACR.AX) as of Oct 20, 2026 is 108,000.00 AUD. In the previous year, Revenue per Employee was 27,674.42 AUD — a change of 290.25% (higher).

Revenue per Employee

108,000.00AUD

YoY

290.25%

Last updated:

Revenue per Employee of Acrux is 2026 108,000.00 AUD. Revenue per Employee of Acrux was 2025 27,674.42 AUD. It decreases by 290.25% higher compared to the previous year.

The Acrux Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2019
14,674.42 AUD
Jan 1, 2020
29,139.53 AUD
Jan 1, 2021
31,093.02 AUD
Jan 1, 2022
39,976.74 AUD
Jan 1, 2023
196,023.26 AUD
Jan 1, 2024
118,395.35 AUD
Jan 1, 2025
27,674.42 AUD
Jan 1, 2026
108,000.00 AUD
The Acrux Revenue per Employee history
YEARRevenue per EmployeeYoY
108,000.00AUD+290.25%
27,674.42AUD-76.63%
118,395.35AUD-39.60%
196,023.26AUD+390.34%
39,976.74AUD+28.57%
31,093.02AUD+6.70%
29,139.53AUD+98.57%
14,674.42AUD-81.61%
79,813.95AUD-85.66%
556,604.65AUD-16.19%
664,116.28AUD+12.57%
589,953.49AUD-52.90%
1.25 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrux Stock analysis

What does Acrux do? Acrux Ltd is an Australian pharmaceutical company specializing in the development and marketing of products in the dermatology field. The company was founded in 1998 and is headquartered in Melbourne. Its history begins with the development of a groundbreaking technology called the "Sprayform® Technology," which allows the administration of liquid medications in spray form, providing numerous advantages compared to traditional administration methods. Acrux obtained the first patent for this technology in 1999 and worked on bringing it to the market. Its business model focuses on licensing its Sprayform® Technology to third parties to advance the development and marketing of products in various therapeutic areas. The company has an experienced research and development team that collaborates closely with partners to develop tailored solutions and support the entire development process, ensuring that all products meet the highest quality standards and regulatory requirements. Acrux Ltd is divided into various divisions, including products for women, diabetes, pain and inflammation, as well as neurology and psychiatry. With its Sprayform® Technology, the company has developed unique therapeutic solutions that meet patients' needs. For example, a testosterone preparation for women has been developed that is simply applied as a spray and offers higher efficacy than traditional tablets. Another product is a fast-acting pain reliever that is administered through a nasal spray. Acrux Ltd also has partnerships with major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, Pfizer, and Sanofi. These partnerships enable Acrux to market its technology globally and offer its customers a comprehensive portfolio of tailored solutions. The partner is granted exclusive rights to use the technology for specific products and markets, facilitating the development of new products and the expansion into new regions. Overall, Acrux Ltd has achieved a leadership position in the field of transdermal systems and transmucosal technologies through its innovative Sprayform® Technology. The company aims to further expand its leadership position by focusing on the development of new products and collaboration with partners. Acrux remains in constant exchange with the scientific community to incorporate the latest research and development insights into its products. Acrux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrux stock

Revenue per Employee of Acrux is 108,000.00 AUD in 2026.

Revenue per Employee of Acrux changed from 27,674.42 AUD to 108,000.00 AUD, representing a 290.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee Acrux since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's Acrux historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Acrux

All Key Metrics — Acrux